Phase 3 Readout~month
Phase 3 Topline: RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing
- Company
- Immunome Inc. (IMNM)
- Drug
- progressing
- Indication
- Desmoid; Desmoid Tumor
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.